Healthcare Industry News: RTI Biologics
News Release - May 15, 2008
RTI Biologics Announces Successful Implantation of First Fresh-Stored Osteochondral Allograft
ALACHUA, Fla.--(HSMN NewsFeed)--RTI Biologics, Inc. (RTI) (Nasdaq:RTIX ), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, announces the successful implantation of its first fresh-stored osteochondral (OC) allograft in Arkansas last Monday.The female patient, 40, with a history of persistent knee pain due to articular cartilage damage, underwent a microfracture procedure approximately one year ago, but the lesion persisted. The fresh-stored OC allograft allowed the surgeon to resurface the defect with mature hyaline cartilage, while providing the patient with a smooth articulating surface.
Fresh-stored OC allografts provide mature hyaline cartilage with subchondral bone for resurfacing articular cartilage damage in the knee. The graft is cleansed, processed and preserved to provide a safe, high-quality allograft with a high level of chondrocyte viability, which enhances efficacy. Like all RTI tissue, extensive donor screening in accordance with Food and Drug Administration (FDA) and American Association of Tissue Banks (AATB) requirements is conducted. In addition to serological testing, microbiological testing is used throughout the process to screen for potential contamination.
“The introduction of RTI’s fresh-stored OC allograft is successfully allowing surgeons to meet more of their patients’ demand for effective cartilage repair through a true biologic solution,” said Drew Distin, RTI’s director of U.S. distribution.
Fresh-stored OC allografts are in full production through RTI's direct representatives and distributors. Anterior-posterior and lateral radiographs are used to size-match grafts to awaiting patients and are currently being accepted by RTI. For further information, contact an RTI representative at (800) 624-7238.
About RTI Biologics Inc.
RTI Biologics, Inc. is the leading provider of sterile biological implants for surgeries around the world with a commitment to advancing science, safety and innovation. RTI prepares human donated tissue and bovine tissue for transplantation through extensive testing and screening, precision shaping and proprietary, validated sterilization processes. These allograft and xenograft implants are used in orthopedic, dental, hernia and other specialty surgeries.
RTI’s innovations continuously raise the bar of science and safety for biologics—from being the first company to offer precision-tooled bone implants and assembled technology to maximize each gift of donation, to inventing fully validated sterilization processes that include viral inactivation steps. Two such processes, the BioCleanse® Tissue Sterilization Process and the Tutoplast® process, sterilize tissue, are clinically successful and are scientifically proven to eliminate donor-to-recipient disease transmission risk while preserving tissue strength and biocompatibility. These processes have a proven record of more than two million implants distributed with zero incidence of infection. In addition, RTI pastes are sterilized through the demineralization process, a validated viral inactivation step.
The company is leading the evolution of biologics once again by offering a bovine based biological matrix, providing surgeons an expanded supply of safe, sterile tissue for their patients.
RTI’s worldwide corporate headquarters are located in Alachua, Fla., with international facilities in Neunkirchen, Germany, and Aix-en-Provence, France. The company is accredited by the American Association of Tissue Banks.
Forward Looking Statement
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements about the expected benefits of the business combination involving RTI and Tutogen, including potential synergies and cost savings, future financial and operating results, and the combined company's plans and objectives. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results, regulatory approvals or changes to agreements with distributors also are forward-looking statements. Forward-looking statements are subject to risks and uncertainties, including the ability of RTI to integrate its business successfully and to realize the expected synergies and cost savings from the merger and the risks described in public filings on file with the Securities and Exchange Commission (SEC). Actual results may differ materially from anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's Web site at www.rtix.com or the SEC's Web site at www.sec.gov.
Source: RTI Biologics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
